Adynamic bone disease - Bone and beyond

NDT Plus

Volumn 1, Issue 3, 2008, Pages 135-147

  Brandenburg, Vincent M ^a   Floege, Jürgen ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Adynamic bone disease; Calcification; Chronic kidney disease; Low turnover osteodystrophy

Indexed keywords

ALFACALCIDOL; ALKALINE PHOSPHATASE BONE ISOENZYME; ALUMINUM; BIOLOGICAL MARKER; CALCIUM; CALCIUM ACETATE; CALCIUM CARBONATE; DEFEROXAMINE; DIAGNOSTIC AGENT; SEVELAMER; TETRACYCLINE; VITAMIN D;

ADYNAMIC BONE DISEASE; ALUMINIUM BONE DISEASE; ALUMINUM OVERLOAD; BLOOD CHEMISTRY; BLOOD VESSEL CALCIFICATION; BONE BIOPSY; BONE DENSITY; BONE DISEASE; BONE PAIN; BONE RADIOGRAPHY; BONE TURNOVER; CALCIFICATION; CALCIUM INTAKE; CALCIUM METABOLISM; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DIALYSIS; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG MEGADOSE; HUMAN; HYPOTHYROIDISM; KIDNEY FAILURE; MORPHOMETRICS; MUSCLE WEAKNESS; NONHUMAN; PARATHYROID HORMONE BLOOD LEVEL; PREVALENCE; PRIORITY JOURNAL; RENAL OSTEODYSTROPHY; REVIEW; RISK FACTOR;

EID: 44449113188     PISSN: 17530784     EISSN: 17530792     Source Type: Journal    
DOI: 10.1093/ndtplus/sfn040     Document Type: Review

References (111)

1. Moe S, Drucke T, Cunningham J et al. Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69: 1945-1953
2. Haas M, Leko-Mohr Z, Roschger P et al. Osteoprotegerin and parathyroid hormone as markers of high-turnover osteodystrophy and decreased bone mineralization in hemodialysis patients. Am J Kidney Dis 2002, 39: 580-586
3. Malluche HH, Monier-Faugere MC. Renal osteodystrophy: What's in a name? Presentation of a clinically useful new model to interpret bone histologic findings. Clin Nephrol 2006; 65: 235-242
4. Ferreira A. Development of renal bone disease. Eur J Clin Invest 2006; 36(Suppl 2): 2-12
5. Parfitt AM. Renal bone disease: A new conceptual framework for the interpretation of bone histomorphometry. Curr Opin Nephrol Hypertens 2003; 12: 387-403
6. Malluche HH, Mawad H, Monier-Faugere MC. The importance of bone health in end-stage renal disease: Out of the frying pan, into the fire? Nephrol Dial Transplant 2004; 19(Suppl1): I9-i13
7. Sherrard DJ, Ott S, Maloney NA. Uremic osteodystrophy, classification, cause, and treatment. In: Frame B, Potts JRJ (eds). Clinical Disorders of Bone and Mineral Metabolism. Amsterdam: Excerpta Medica, 1983, 254-259
8. Malluche HH, Faugere MC. Atlas of Mineralized Bone Histology. Basel: Karger, 1986
9. Spasovski GB. Bone biopsy as a diagnostic tool in the assessment of renal osteodystrophy. Int J Artif Organs 2004; 27: 918-923
10. Cannata-Andia JB. Hypokinetic azotemic osteodystrophy. Kidney Int l998; 54: 1000-1016
11. Hernandez CJ, Hazelwood SJ, Martin RB. The relationship between basic multicellular unit activation and origination in cancellous bone. Bone 1999; 25: 585-587
12. Ballanti P, Coen G, Mazzaferro S et al. Histomorphometric assessment of bone turnover in uraemic patients: Comparison between activation frequency and bone formation rate. Histopathology 2001; 38: 571-583
13. Haris A, Sherrard DJ, Hercz G. Reversal of adynamic bone disease by lowering of dialysate calcium. Kidney Int 2006; 70: 931-937
14. Monier-Faugere MC, Malluche HH. Trends in renal osteodystrophy: A survey from 1983 to 1995 in a total of 2248 patients. Nephrol Dial Transplant 1996; 11(Suppl 3): 111-120
15. Barreto DV, Barreto FC, Carvalho AB et al. Coronary calcification in hemodialysis patients: The contribution of traditional and uremiarelated risk factors. Kidney Int 2005; 67: 1576-1582
16. Salusky IB, Coburn JW, Brill J et al. Bone disease in pediatric patients undergoing dialysis with CAPD or CCPD. Kidney Int 1988; 33: 975-982
17. Andress DL, Nebeker HG, Ott SM et al. Bone histologic response to deferoxamine in aluminum-related bone disease. Kidney Int 1987; 31: 1344-1350
18. Sherrard DJ, Hercz G, Pei Y et al. The spectrum of bone disease in end-stage renal failure - an evolving disorder. Kidney Int 1993; 43: 436-442
19. Torres A, Lorenzo V, Hernandez D et al. Bone disease in predialysis, hemodialysis, and CAPD patients: Evidence ofa better bone response to PTH. Kidney Int 1995; 47: 1434-1442
20. Lehmann G, Stein G, Huller M et al. Specific measurement of PTH (1-84) in various forms of renal osteodystrophy (ROD) as assessed by bone histomorphometry. Kidney Int 2005; 68: 1206-1214
21. Spasovski GB, Bervoets AR, Behets GJ et al. Spectrum of renal bone disease in end-stage renal failure patients not yet on dialysis. Nephrol Dial Transplant 2003; 18: 1159-1166
22. Bervoets AR, Spasovski GB, Behets GJ et al. Useful biochemical markers for diagnosing renal osteodystrophy in predialysis end-stage renal failure patients. Am J Kidney Dis 2003; 41: 997-1007
23. Rocha LA, Higa A, Barreto FC et al. Variant of adynamic bone disease in hemodialysis patients: Fact or fiction? Am J Kidney Dis 2006; 48: 430-436
24. Llach F, Felsenfeld AJ, Coleman MD et al. The natural course of dialysis osteomalacia. Kidney Int Suppl 1996; 19: S74-S79
25. Schwarz C, Sutzbacher I, Oberbauer R. Diagnosis of renal osteodystrophy. Eur J Clin Invest 2006, 36(Suppl 2): 13-22
26. Cannata-Andia JB. Pathogenesis, prevention and management of low-bone turnover. Nephrol Dial Transplant 2000; 15(Suppl 5): 15-17
27. Malluche HH, Monier-Faugere MC. The role of bone biopsy in the management of patients with renal osteodystrophy. J Am Soc Nephrol 1994; 4: 1631-1642
28. Urena P, De Vernejoul MC. Circulating biochemical markers of bone remodeling in uremic patients. Kidney Int 1999; 55: 2141-2156
29. Barreto FC, Barreto DV, Moyses RM et al. K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients. Kidney Int 2008; 73: 771-777
30. Ferreira A, Frazao JM, Monier-Faugere MC et al. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol 2008; 19: 405-412
31. Goodman WG. Comments on plasma parathyroid hormone levels and their relationship to bone histopathology among patients undergoing dialysis. Semin Dial 2007; 20: 1-4
32. Goodman WG. The evolution of assays for parathyroid hormone. Semin Dial 2005; 18: 296-301
33. Monier-Faugere MC, Geng Z, Mawad H et al. Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patients. Kidney Int 2001; 60: 1460-1468
34. Berlyne GM, Ben Ari J, Pest D et al. Hyperaluminaemia from aluminum resins in renal failure. Lancet 1970; 2: 494-496
35. Nebeker HG, Coburn JW. Aluminum and renal osteodystrophy. Annu Rev Med 1986; 37: 79-95
36. Savory J, Bertholf RL, Wills MR. Aluminium toxicity in chronic renal insufficiency. Clin Endocrinol Metab 1985; 14: 681-702
37. Ott SM, Maloney NA, Coburn JW et al. The prevalence of bone aluminum deposition in renal osteodystrophy and its relation to the response to calcitriol therapy. N Engl J Med 1982; 307: 709-713
38. Morrissey J, Slatopolsky E. Effect of aluminum on parathyroid hormone secretion. Kidney Int Suppl 1986; 18: S41-S44
39. Diaz-Corte C, Fernandez-Martin JL, Barreto S et al. Effect of aluminium load on parathyroid hormone synthesis. Nephrol Dial Transplant 2001; 16: 742-745
40. Gonzalez-Suarez I, Naves M, Diaz-Corte C et al. Effect of aluminium on calcium-sensing receptor expression, proliferation, and apoptosis of parathyroid glands from rats with chronic renal failure. Kidney Int Suppl 2003; 63: S39-S43
41. Felsenfeld AJ, Gutman RA, Llach F et al. Harrelson JM. Osteomalacia in chronic renal failure: A syndrome previously reported only with maintenance dialysis. Am J Nephrol 1982; 2: 147-154
42. London GM, Marty C, Marchais SJ et al. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 2004; 15: 1943-1951
43. Jorgetti V, Lopez BD, Caorsi H et al. Different patterns of renal osteodystrophy in Iberoamerica. Am J Med Sci 2000; 320: 76-80
44. D'Haese PC, Couttenye MM, Goodman WG et al. Use of the low-dose desferrioxamine test to diagnose and differentiate between patients with aluminium-related bone disease, increased risk for aluminium toxicity, or aluminium overload. Nephrol Dial Transplant 1995; 10: 1874-1884
45. Milliner DS, Nebeker HG, Ott SM et al. Use of the deferoxamine infusion test in the diagnosis of aluminum-related osteodystrophy. Ann Intern Med 1984; 101: 775-779
46. Nebeker HG, Andress DL, Milliner DS et al. Indirect methods for the diagnosis of aluminum bone disease: Plasma aluminum, the desferrioxamine infusion test, and serum iPTH. Kidney Int Suppl 1986; 18: S96-S99
47. Walton JR, Diamond TH, Kumar S et al. A sensitive stain for aluminum in undecalcified cancellous bone. J Inorg Biochem 2007; 101: 1285-1290
48. Hodsman AB, Steer BM. Serum aluminum levels as a reflection of renal osteodystrophy status and bone surface aluminum staining. J Am Soc Nephrol 1992; 2: 1318-1327
49. Hamdy NA, Kanis JA, Beneton MN et al. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ 1995; 310: 358-363
50. Coen G, Mazzaferro S, Ballanti P et al. Renal bone disease in 76 patients with varying degrees of predialysis chronic renal failure: A cross-sectional study. Nephrol Dial Transplant 1996; 11: 813-819
51. Coen G, Ballanti P, Bonucci E et al. Renal osteodystrophy in predialysis and hemodialysis patients: Comparison of histologic patterns and diagnostic predictivity of intact PTH. Nephron 2002; 91: 103-111
52. Martin KJ, Olgaard K, Coburn JW et al. Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy. Am J Kidney Dis 2004; 43: 558-565
53. Hutchison AJ, Moore PR. Low turnover bone disease. Perit Dial Int 1996; 16(Suppl 1); S295-S299
54. Langub MC, Monier-Faugere MC, Wang G et al. Administration of PTH-(7-84) antagonizes the effects of PTH-(1-84) on bone in rats with moderate renal failure. Endocrinology 2003; 144: 1135-1138
55. Yajima A, Ogawa Y, Ikehara A et al. Development of low-turnover bone diseases after parathyroidectomy and autotransplantation. Int J Urol 2001, 8: S76-S79
56. Picton ML, Moore PR, Mawer EB et al. Down-regulation of human osteoblast PTH/PTHrP receptor mRNA in end-stage renal failure. Kidney Int 2000; 58: 1440-1449
57. Iwasaki-Ishizuka Y, Yamato H, Nii-Kono T et al. Downregulation of parathyroid hormone receptor gene expression and osteoblastic dysfunction associated with skeletal resistance to parathyroid hormone in a rat model of renal failure with low turnover bone. Nephrol Dial Transplant 2005; 20: 1904-1911
58. Vincenti F, Arnaud SB, Recker R et al. Parathyroid and bone response of the diabetic patient to uremia. Kidney Int 1984; 25: 677-682
59. Andress DL, Herez G, Kopp JB et al. Bone histomorphometry of renal osteodystrophy in diabetic patients. J Bone Miner Res 1987; 2: 525-531
60. Couttenye MM, D'Haese PC, Verschoren WJ et al. Low bone turnover in patients with renal failure. Kidney Int Suppl 1999; 73: S70-S76
61. Hendy GN, Hruska KA, Mathew S et al. New insights into mineral and skeletal regulation by active forms of vitamin D. Kidney Int 2006; 69: 218-223
62. Baker LR, Abrams SM, Roe CJ et al. Early therapy of renal bone disease with calcitriol: A prospective double-blind study. Kidney Int Suppl 1989; 27: S140-S142
63. Goodman WG, Ramirez JA, Belin TR et al. Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 1994; 46: 1160-1166
64. Slatopolsky E, Weerts C, Thielan J et al. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. J Clin Invest 1984; 74: 2136-2143
65. Malluche HH, Momer-Faugere MC. Risk of adynamic bone disease in dialyzed patients. Kidney Int Suppl 1992; 38: S62-S67
66. Pei Y, Hercz G, Greenwood C et al. Renal osteodystrophy in diabetic patients. Kidney Int 1993; 44: 159-164
67. Kurz P, Tsobanelis T, Roth P et al. Differences in calcium kinetic pattern between CAPD and HD patients. Clin Nephrol 1995; 44: 255-261
68. Hernandez JD, Wesseling K, Boechat MI et al. Osteomalacia in a hemodialysis patient receiving an active vitamin D sterol. Nat Clin Pract Nephrol 2007; 3: 227-232
69. Alfrey AC, LeGendre GR, Kaehny WD. The dialysis encephalopathy syndrome. Possible aluminum intoxication. N Engl J Med 1976; 294: 184-188
70. Kurz P, Monier-Faugere MC, Bognar B et al. Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int 1994; 46: 855-861
71. Meric F, Yap P, Bia MJ. Etiology of hypercalcemia in hemodialysis patients on calcium carbonate therapy. Am J Kidney Dis 1990; 16: 459-464
72. Hercz G, Pei Y, Greenwood C et al. Aplastic osteodystrophy without aluminum: The role of "suppressed" parathyroid function. Kidney Int 1993; 44: 860-866
73. Kestenbaum B, Belozeroff V. Mineral metabolism disturbances in patients with chronic kidney disease. Eur J Clin Invest 2007, 37: 607-622
74. Westenfeld R, Jahnen-Dechent W, Ketteler M. Vascular calcification and fetuin-A deficiency in chronic kidney disease. Trends Cardiovasc Med 2007; 17: 124-128
75. Kalpakian MA, Mehrotra R. Vascular calcification and disordered mineral metabolism in dialysis patients. Semin Dial 2007; 20: 139-143
76. Asci G. The link between cardiovascular and bone disease in hemodialysis patients (abstract). Nephrol Dial.Transplant 2007; 22(S6): 217
77. Mawad HW, Sawaya BP, Sarin R et al. Calcific uremic arteriolopathy in association with low turnover uremic bone disease. Clin Nephrol 1999; 52: 160-166
78. Davies MR, Lund RJ, Mathew S et al. Low turnover osteodystrophy and vascular calcification are amenable to skeletal anabolism in an animal model of chronic kidney disease and the metabolic syndrome. J Am Soc Nephrol 2005; 16: 917-928
79. Shao JS, Cheng SL, Charlton-Kachigian N et al. Teriparatide (human parathyroid hormone (1-34)) inhibits osteogenic vascular calcification in diabetic low density lipoprotein receptor-deficient mice. J Biol Chem 2003; 278: 50195-50202
80. Kalantar-Zadeh K, Kuwae N, Regidor DL et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70: 771-780
81. Ganesh SK, Stack AG, Levin NW et al. Association of elevated serum PO(4), Ca × PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001; 12: 2131-2138
82. Avram MM, Mittman N, Myint MM et al. Importance of low serum intact parathyroid hormone as a predictor of mortality in hemodialysis and peritoneal dialysis patients: 14 years of prospective observation. Am J Kidney Dis 2001; 38: 1351-1357
83. Guh JY, Chen HC, Chuang HY et al. Risk factors and risk for mortality of mild hypoparathyroidism in hemodialysis patients. Am J Kidney Dis 2002; 39: 1245-1254
84. Stevens LA, Djurdjev O, Cardew S et al. Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: Evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol 2004; 15: 770-779
85. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218
86. Atsumi K, Kushida K, Yamazaki K et al. Risk factors for vertebral fractures in renal osteodystropby. Am J Kidney Dis 1999, 33: 287-293
87. Danese MD, Kim J, Doan QV et al. PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. Am J Kidney Dis 2006; 47: 149-156
88. Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 2000; 36: 1115-1121
89. Kuizon BD, Goodman WG, Juppner H et al. Diminished linear growth during intermittent calcitriol therapy in children undergoing CCPD. Kidney Int 1998; 53: 205-211
90. Martin KJ, Gonzalez EA. Metabolic bone disease in chronic kidney disease. J Am Soc Nephrol 2007; 18: 875-885
91. D'Haese PC, Spasovski GB, Sikole A et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl 2003; 63: S73-S78
92. Teng M, Wolf M, Ofsthun MN et al. Activated injectable vitamin D and hemodialysis survival: A historical cohort study. J Am Soc Nephrol 2005; 16: 1115-1125
93. Finch JL, Bergfeld M, Martin KJ et al. The effects of discontinuation of aluminum exposure on aluminum-induced osteomalacia. Kidney Int 1986; 30: 318-324
94. Jablonski G, Klem KH, Danielsen CC et al. Aluminium-induced bone disease in uremic rats: Effect of deferoxamine. Biosci Rep 1996; 16: 49-63
95. McCarthy JT, Milliner DS, Johnson WJ. Clinical experience with desferrioxamine in dialysis patients with aluminium toxicity. Q J Med 1990; 74: 257-276
96. Molitoris BA, Alfrey AC, Alfrey PS et al. Rapid removal of DFO-chelated aluminum during hemodialysis using polysulfone dialyzers. Kidney Int 1988; 34: 98-101
97. Andress DL, Ott SM, Maloney NA et al. Effect of parathyroidectomy on bone aluminum accumulation in chronic renal failure. N Engl J Med 1985; 312: 468-473
98. Spasovski G, Gelev S, Masin-Spasovska J et al. Improvement of bone and mineral parameters related to adynamic bone disease by diminishing dialysate calcium. Bone 2007; 41: 698-703
99. Lezaic V, Pejanovic S, Kostic S et al. Effects of lowering dialysate calcium concentration on mineral metabolism and parathyroid hormone secretion: A multicentric study. Ther Apher Dial 2007; 11: 121-130
100. Fujimori A, Yorifuji M, Sakai M et al. Low-calcium dialysate improves mineral metabolism in hemodialysis patients. Clin Nephrol 2007; 67: 20-24
101. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245-252
102. Raggi P, James G, Burke SK et al. Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis. J Bone Miner Res 2005; 20: 764-772
103. Asmus HG, Braun J, Krause R et al. Two year comparison of seve-lamer and calcium carbonate effects on cardiovascular calcification and bone density. Nephrol Dial Transplant 2005; 20: 1653-1661
104. Sanchez CP, Kuizon BD, Abdella PA et al. Impaired growth, delayed ossification, and reduced osteoclastic activity in the growth plate of calcium-supplemented rats with renal failure. Endocrinology 2000; 141: 1536-1544
105. Balint E, Marshall CF, Sprague SM. Effect of the vitamin D analogues paricalcitol and calcitriol on bone mineral in vitro. Am J Kidney Dis 2000; 36: 789-796
106. Monier-Faugere MC, Mawad H, Malluche HH. Opposite effects of calcitriol and paricalcitol on the parathyroid hormone-(1-84)/large carboxy-terminal-parathyroid hormone fragments ratio in patients with stage 5 chronic kidney disease. Clin J Am Soc Nephrol 2007; 2: 1255-1260
107. Winer KK, Ko CW, Reynolds JC et al. Long-term treatment of hypoparathyroidism: A randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium. J Clin Endocrinol Metab 2003; 88: 4214-4220
108. Silver J, Bushinsky D. Harnessing the parathyroids to create stronger bones. Curr Opin Nephrol Hypertens 2004; 13: 471-476
109. Goodman WG, Hladik GA, Turner SA et al. The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 2002; 13: 1017-1024
110. Ishii H, Wada M, Furuya Y et al. Daily intermittent decreases in serum levels of parathyroid hormone have an anabolic-like action on the bones of uremic rats with low-turnover bone and osteomalacia. Bone 2000; 26: 175-182
111. Gowen M, Stroup GB, Dodds RA et al. Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats. J Clin Invest 2000; 105: 1595-1604